Plasma cell myeloma recurrent
Not recruitingStudy Comparing Subcutaneous and Intravenous Isatuximab with Pomalidomide and Dexamethasone for Adults with Relapsed or Refractory Multiple Myeloma
Study Comparing Subcutaneous and Intravenous Isatuximab with Pomalidomide and Dexamethasone for Adults with Relapsed or Refractory Multiple Myeloma
- Disease:Plasma cell myeloma recurrent
- Substances:DexamethasoneIsatuximab+2
France- Participants:65+ years
- Substances:Dexamethasone
- Sponsor:Sanofi-Aventis Recherche & Developpement










